Draft guidance released by CMS in November on the use of coverage with evidence development (CED) for determining Medicare coverage elicited industry concerns. The guidance suggests available data used to obtain FDA OKs "will rarely be sufficient for Medicare coverage," creating more confusion on the use of CED, said Chandra Branham of the Advanced Medical Technology Association.
CMS coverage guidance draws medtech, drug industry concerns
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||